Lam Research rallies as advanced-packaging R&D expansion and a bullish analyst call lift sentiment

Lam Research Corporation (LRCX) is up 5.9% today. Here is some analysis on what might have caused this price movement.

Analysis: Shares appear to be reacting to fresh positive catalysts tied to advanced chip packaging and AI-driven semiconductor spending. A newly announced packaging-focused R&D expansion in Austria, alongside a recent bullish Wall Street analyst upgrade, likely boosted expectations for incremental growth and share gains.

Details:

Lam opened a new research lab in Salzburg, Austria, aimed at advancing chip-packaging technology designed to increase chip density and reduce overall packaging costs.

The company’s advanced-packaging narrative has been a key part of its recent growth story as AI accelerates demand for higher-performance compute and memory systems.

Morgan Stanley recently upgraded Lam Research to Overweight and raised its price target (published May 18, 2026), helping reinforce bullish sentiment around the equipment cycle.

Lam’s most recent quarterly results and forward guidance (released April 22, 2026) pointed to continued momentum, which can amplify stock reactions to follow-on positive news.

Sources:

MarketBeat, Investing.com, Lam Research Investor Relations

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$LRCX Insider Trading Activity

$LRCX insiders have traded $LRCX stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.

Here’s a breakdown of recent trading of $LRCX stock by insiders over the last 6 months:

TIMOTHY ARCHER (President and CEO) has made 0 purchases and 2 sales selling 163,300 shares for an estimated $26,758,338.
DOUGLAS R BETTINGER (Chief Financial Officer & EVP) has made 0 purchases and 2 sales selling 90,386 shares for an estimated $20,498,812.
ERIC BRANDT has made 0 purchases and 2 sales selling 35,000 shares for an estimated $7,896,150.
NEIL J FERNANDES (Senior Vice President) sold 18,170 shares for an estimated $4,635,893
AVA HARTER (Chief Legal Officer) has made 0 purchases and 3 sales selling 11,510 shares for an estimated $2,818,536.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$LRCX Hedge Fund Activity

We have seen 1,236 institutional investors add shares of $LRCX stock to their portfolio, and 1,209 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 6,893,278 shares (+25.8%) to their portfolio in Q1 2026, for an estimated $1,417,947,284
JPMORGAN CHASE & CO removed 6,436,253 shares (-21.5%) from their portfolio in Q4 2025, for an estimated $1,101,757,788
GOLDMAN SACHS GROUP INC removed 4,359,777 shares (-29.4%) from their portfolio in Q1 2026, for an estimated $896,806,128
CORIENT PRIVATE WEALTH LLC removed 4,093,544 shares (-78.7%) from their portfolio in Q1 2026, for an estimated $842,042,000
J. STERN & CO. LLP removed 3,439,713 shares (-99.4%) from their portfolio in Q1 2026, for an estimated $707,548,964
CITADEL ADVISORS LLC removed 3,126,734 shares (-73.7%) from their portfolio in Q1 2026, for an estimated $643,169,183
ARTISAN PARTNERS LIMITED PARTNERSHIP removed 2,921,363 shares (-36.7%) from their portfolio in Q1 2026, for an estimated $600,924,369

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$LRCX Congressional Stock Trading

Members of Congress have traded $LRCX stock 11 times in the past 6 months. Of those trades, 3 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $LRCX stock by members of Congress over the last 6 months:

REPRESENTATIVE DAVID TAYLOR has traded it 8 times. They made 1 purchase worth up to $15,000 on 03/12 and 7 sales worth up to $175,000 on 04/27, 02/26, 01/16, 01/08.
REPRESENTATIVE CLEO FIELDS purchased up to $50,000 on 02/03.
SENATOR JOHN BOOZMAN sold up to $15,000 on 01/08.
SENATOR MARKWAYNE MULLIN purchased up to $100,000 on 12/29.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$LRCX Analyst Ratings

Wall Street analysts have issued reports on $LRCX in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 01/29/2026
Goldman Sachs issued a "Buy" rating on 01/29/2026
RBC Capital issued a "Outperform" rating on 01/15/2026
Wells Fargo issued a "Overweight" rating on 01/15/2026
Bernstein issued a "Outperform" rating on 01/12/2026
Mizuho issued a "Outperform" rating on 01/09/2026
B. Riley Securities issued a "Buy" rating on 12/18/2025

To track analyst ratings and price targets for $LRCX, check out Quiver Quantitative's $LRCX forecast page.

$LRCX Price Targets

Multiple analysts have issued price targets for $LRCX recently. We have seen 22 analysts offer price targets for $LRCX in the last 6 months, with a median target of $300.0.

Here are some recent targets:

Shane Brett from Morgan Stanley set a target price of $331.0 on 05/18/2026
Jay Goldberg from Seaport Global set a target price of $300.0 on 05/05/2026
Tom O'Malley from Barclays set a target price of $275.0 on 04/23/2026
Charles Shi from Needham set a target price of $300.0 on 04/23/2026
Vivek Arya from B of A Securities set a target price of $330.0 on 04/23/2026
Atif Malik from Citigroup set a target price of $315.0 on 04/23/2026
Brian Chin from Stifel set a target price of $325.0 on 04/23/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.